Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects

European Psychiatry

Volumn 30, Issue 4, 2015, Pages 504-510

  Zhang, G F ^a   Liu, W X ^a   Qiu, L L ^a   Guo, J ^b   Wang, X M ^a   Sun, H L ^a   Yang, J J ^a,c,d   Zhou, Z Q ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

^d Jiangsu Province Key Laboratory of Anesthetic and Analgesic Application Technology   (China)

Author keywords

Behavior; Citalopram; Depression; Ketamine

Indexed keywords

CITALOPRAM; KETAMINE; ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; FORCED SWIM TEST; LAG TIME; MALE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; STEREOTYPY; STRESS; SUCROSE PREFERENCE TEST; TREATMENT RESPONSE; ANIMAL; ANIMAL BEHAVIOR; DEPRESSIVE DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; EXPLORATORY BEHAVIOR; SWIMMING; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CITALOPRAM; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; KETAMINE; RATS; RATS, WISTAR; SWIMMING;

EID: 84930865817     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2014.11.007     Document Type: Article

References (48)

1. aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2009, 67(2):139-145.
2. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999, 156(10):1646-1649.
3. Araya-Callís C., Hiemke C., Abumaria N., Flugge G. Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus. Psychopharmacology (Berl) 2012, 224(1):209-222.
4. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475(7354):91-95.
5. Bergman S.A. Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 1999, 46(1):10-20.
6. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47(4):351-354.
7. Beurel E., Song L., Jope R.S. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011, 16(11):1068-1070.
8. Browne C.A., Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013, 4:161.
9. Chaviaras S., Mak P., Ralph D., Krishnan L., Broadbear J.H. Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology (Berl) 2010, 210(1):35-43.
10. Cornwell B.R., Salvadore G., Furey M., Marquardt C.A., Brutsche N.E., Grillon C., et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 2012, 72(7):555-561.
11. de Oliveira L., Fraga D.B., De Luca R.D., Canever L., Ghedim F.V., Matos M.P., et al. Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine. Metab Brain Dis 2011, 26(1):69-77.
12. Garcia L.S., Comim C.M., Valvassori S.S., Réus G.Z., Stertz L., Kapczinski F., et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(3):450-455.
13. Gigliucci V., O'Dowd G., Casey S., Egan D., Gibney S., Harkin A. Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology (Berl) 2013, 228(1):157-166.
14. Huang N.K., Wan F.J., Tseng C.J., Tung C.S. Amphetamine induces hydroxyl radical formation in the striatum of rats. Life Sci 1997, 61(22):2219-2229.
15. Ibrahim L., Diaz Granados N., Jolkovsky L., Brutsche N., Luckenbaugh D.A., Herring W.J., et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 2012, 32(4):551-557.
16. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59(6):530-537.
17. Kim H., Chen L., Lim G., Sung B., Wang S., McCabe M.F., et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 2012, 122(8):2940-2954.
18. Krishnan V., Nestler E.J. Animal models of depression: molecular perspectives. Curr Top Behav Neurosci 2011, 7:121-147.
19. Lapmanee S., Charoenphandhu J., Charoenphandhu N. Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety-and depression-like behaviors. Behav Brain Res 2013, 250:316-325.
20. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329(5994):959-964.
21. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011, 69(8):754-761.
22. Liu Q., Yu J., Mao-Ying Q.L., Mi W.L., Li B., Wang Y.Q., et al. Repeated clomipramine treatment reversed the inhibition of cell proliferation in adult hippocampus induced bychronic unpredictable stress. Pharmacogenomics J 2008, 8(6):375-383.
23. Ma X.C., Dang Y.H., Jia M., Ma R., Wang F., Wu J., et al. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 2013, 8(2):e56053.
24. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63(4):349-352.
25. Monteggia L.M., Gideons E., Kavalali E.T. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 2013, 73(12):1199-1203.
26. Murrough J.W., Iosifescu D.V., Chang L.C., Al Jurdi R.K., Green C.E., Perez A.M., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013, 170(10):1134-1142.
27. Murrough J.W., Perez A.M., Pillemer S., Stern J., Parides M.K., aan het Rot M., et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013, 74(4):250-256.
28. Nakajima S., Suzuki T., Watanabe K., Kashima H., Uchida H. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(2):259-264.
29. Nishitani N., Nagayasu K., Asaoka N., Yamashiro M., Shirakawa H., Nakagawa T., et al. Raphe AMPA receptors and nicotinic acetylcholine receptors mediate ketamine-induced serotonin release in the rat prefrontal cortex. Int J Neuropsychopharmacol 2014, 17(8):1321-1326.
30. Owolabi R.A., Akanmu M.A., Adeyemi O.I. Effects of ketamine and N-methyl-d-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test. Neurosci Lett 2014, 566:172-176.
31. Parise E.M., Alcantara L.F., Warren B.L., Wright K.N., Hadad R., Sial O.K., et al. Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. Biol Psychiatry 2013, 74(10):750-759.
32. Perry E.B., Cramer J.A., Cho H.S., Petrakis I.L., Karper L.P., Genovese A., et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007, 192(2):253-260.
33. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist. CP-101,606, in patients ithtreatment-refractory majord epressive disorder. J Clin Psychopharmacol 2008, 28(6):631-637.
34. Rushforth S.L., Steckler T., Shoaib M. Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure. Neuropsychopharmacology 2011, 36(13):2774-2781.
35. Shiroma P.R., Johns B., Kuskowski M., Wels J., Thuras P., Albott C.S., et al. Augmentation of response and remission to serial intravenous; subanesthetic ketamine in treatment resistant depression. J Affect Disord 2014, 155:123-129.
36. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20years on. Trends Pharmacol Sci 2009, 30(11):563-569.
37. Szymkowicz S.M., Finnegan N., DaleR M. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord 2013, 147(1-3):416-420.
38. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005, 66(8):974-981.
39. Tokita K., Yamaji T., Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav 2012, 100(4):688-704.
40. Tomiya M., Fukushima T., Kawai J., Aoyama C., Mitsuhashi S., Santa T., et al. Alterations of plasma and cerebrospinal fluid glutamate levels in rats treated with the N-methyl-D-aspartate receptor antagonist, ketamine. Biomed Chromatogr 2006, 20(6-7):628-633.
41. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40.
42. Wang X., Yang Y., Zhou X., Wu J., Li J., Jiang X., et al. Propofol pretreatment increases antidepressant-like effects induced by acute administration of ketamine in rats receiving forced swimming test. Psychiatry Res 2011, 185(1-2):248-253.
43. Yang J., Pei Y., Pan Y.L., Jia J., Shi C., Yu Y., et al. Enhanced antidepressant-like effects of electroacupuncture combined with citalopram in a rat model of depression. Evid Based Complement Alternat Med 2013, 2013:107380.
44. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63(8):856-864.
45. Zarate C.A., Brutsche N.E., Ibrahim L., Franco-Chaves J., Diazgranados N., Cravchik A., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012, 71(11):939-946.
46. Zhang G.F., Wang N., Shi J.Y., Xu S.X., Li X.M., Ji M.H., et al. Inhibition of L-arginine-nitric oxide pathway mediates the antidepressant effects of ketamine on rats in the forced swimming test. Pharmacol Biochem Behav 2013, 110:8-12.
47. Zhou Z., Zhang G., Li X., Liu X., Wang N., Qiu L., et al. Loss of phenotype of parvalbumin interneurons in rat prefrontal cortex is involved in antidepressant- and propsychotic-like behaviors following acute and repeatedketamine administration. Mol Neurobiol 2014, [Epub ahead of print].
48. Zuo D.Y., Wu Y.L., Yao W.X., Cao Y., Wu C.F., Tanaka M. Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Pharmacol Biochem Behav 2007, 86(1):1-7.